1887

Abstract

Oncolytic virus (OV) therapy is an emerging anti-cancer approach that utilizes viruses to preferentially infect and kill cancer cells, while not harming healthy cells. Vesicular stomatitis virus (VSV) is a prototypic non-segmented, negative-strand RNA virus with inherent OV qualities. Antiviral responses induced by type I interferon pathways are believed to be impaired in most cancer cells, making them more susceptible to VSV than normal cells. Several other factors make VSV a promising OV candidate for clinical use, including its well-studied biology, a small, easily manipulated genome, relative independence of a receptor or cell cycle, cytoplasmic replication without risk of host-cell transformation, and lack of pre-existing immunity in humans. Moreover, various VSV-based recombinant viruses have been engineered via reverse genetics to improve oncoselectivity, safety, oncotoxicity and stimulation of tumour-specific immunity. Alternative delivery methods are also being studied to minimize premature immune clearance of VSV. OV treatment as a monotherapy is being explored, although many studies have employed VSV in combination with radiotherapy, chemotherapy or other OVs. Preclinical studies with various cancers have demonstrated that VSV is a promising OV; as a result, a human clinical trial using VSV is currently in progress.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.046672-0
2012-12-01
2021-10-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/12/2529.html?itemId=/content/journal/jgv/10.1099/vir.0.046672-0&mimeType=html&fmt=ahah

References

  1. Alain T., Lun X., Martineau Y., Sean P., Pulendran B., Petroulakis E., Zemp F. J., Lemay C. G., Roy D. other authors 2010; Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 107:1576–1581 [View Article][PubMed]
    [Google Scholar]
  2. Altomonte J., Braren R., Schulz S., Marozin S., Rummeny E. J., Schmid R. M., Ebert O. 2008a; Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 48:1864–1873 [View Article][PubMed]
    [Google Scholar]
  3. Altomonte J., Wu L., Chen L., Meseck M., Ebert O., García-Sastre A., Fallon J., Woo S. L. 2008b; Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo . Mol Ther 16:146–153 [View Article][PubMed]
    [Google Scholar]
  4. Altomonte J., Wu L., Meseck M., Chen L., Ebert O., Garcia-Sastre A., Fallon J., Mandeli J., Woo S. L. 2009; Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 16:266–278[PubMed]
    [Google Scholar]
  5. Ausubel L. J., Meseck M., Derecho I., Lopez P., Knoblauch C., McMahon R., Anderson J., Dunphy N., Quezada V. other authors 2011; Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment. Hum Gene Ther 22:489–497 [View Article][PubMed]
    [Google Scholar]
  6. Ayala-Breton C., Barber G. N., Russell S. J., Peng K. W. 2012; Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 23:484–491 [View Article][PubMed]
    [Google Scholar]
  7. Balachandran S., Barber G. N. 2004; Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51–65 [View Article][PubMed]
    [Google Scholar]
  8. Balachandran S., Barber G. N. 2007; PKR in innate immunity, cancer, and viral oncolysis. Methods Mol Biol 383:277–301[PubMed]
    [Google Scholar]
  9. Ball L. A., Pringle C. R., Flanagan B., Perepelitsa V. P., Wertz G. W. 1999; Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73:4705–4712[PubMed]
    [Google Scholar]
  10. Barber G. N. 2004; Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17:516–527 [View Article][PubMed]
    [Google Scholar]
  11. Barber G. N. 2005; VSV-tumor selective replication and protein translation. Oncogene 24:7710–7719 [View Article][PubMed]
    [Google Scholar]
  12. Bergman I., Griffin J. A., Gao Y., Whitaker-Dowling P. 2007; Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int J Cancer 121:425–430 [View Article][PubMed]
    [Google Scholar]
  13. Bi Z., Barna M., Komatsu T., Reiss C. S. 1995; Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 69:6466–6472[PubMed]
    [Google Scholar]
  14. Black B. L., Rhodes R. B., McKenzie M., Lyles D. S. 1993; The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J Virol 67:4814–4821[PubMed]
    [Google Scholar]
  15. Boudreau J. E., Bridle B. W., Stephenson K. B., Jenkins K. M., Brunellière J., Bramson J. L., Lichty B. D., Wan Y. 2009; Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther 17:1465–1472 [View Article][PubMed]
    [Google Scholar]
  16. Breitbach C. J., De Silva N. S., Falls T. J., Aladl U., Evgin L., Paterson J., Sun Y. Y., Roy D. G., Rintoul J. L. other authors 2011; Targeting tumor vasculature with an oncolytic virus. Mol Ther 19:886–894 [View Article][PubMed]
    [Google Scholar]
  17. Bridle B. W., Stephenson K. B., Boudreau J. E., Koshy S., Kazdhan N., Pullenayegum E., Brunellière J., Bramson J. L., Lichty B. D., Wan Y. 2010; Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18:1430–1439 [View Article][PubMed]
    [Google Scholar]
  18. Brown C. W., Stephenson K. B., Hanson S., Kucharczyk M., Duncan R., Bell J. C., Lichty B. D. 2009; The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83:552–561 [View Article][PubMed]
    [Google Scholar]
  19. Cary Z. D., Willingham M. C., Lyles D. S. 2011; Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo . J Virol 85:5708–5717 [View Article][PubMed]
    [Google Scholar]
  20. Chakraborty P., Seemann J., Mishra R. K., Wei J. H., Weil L., Nussenzveig D. R., Heiber J., Barber G. N., Dasso M., Fontoura B. M. 2009; Vesicular stomatitis virus inhibits mitotic progression and triggers cell death. EMBO Rep 10:1154–1160 [View Article][PubMed]
    [Google Scholar]
  21. Chang G., Xu S., Watanabe M., Jayakar H. R., Whitt M. A., Gingrich J. R. 2010; Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J Urol 183:1611–1618 [View Article][PubMed]
    [Google Scholar]
  22. Chauhan V. S., Furr S. R., Sterka D. G. Jr, Nelson D. A., Moerdyk-Schauwecker M., Marriott I., Grdzelishvili V. Z. 2010; Vesicular stomatitis virus infects resident cells of the central nervous system and induces replication-dependent inflammatory responses. Virology 400:187–196 [View Article][PubMed]
    [Google Scholar]
  23. Chelbi-Alix M. K., Quignon F., Pelicano L., Koken M. H., de Thé H. 1998; Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 72:1043–1051[PubMed]
    [Google Scholar]
  24. Connor J. H., Lyles D. S. 2002; Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1. J Virol 76:10177–10187 [View Article][PubMed]
    [Google Scholar]
  25. Coulon P., Deutsch V., Lafay F., Martinet-Edelist C., Wyers F., Herman R. C., Flamand A. 1990; Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J Gen Virol 71:991–996 [View Article][PubMed]
    [Google Scholar]
  26. Cripe T. P., Wang P. Y., Marcato P., Mahller Y. Y., Lee P. W. 2009; Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 17:1677–1682 [View Article][PubMed]
    [Google Scholar]
  27. Cureton D. K., Massol R. H., Whelan S. P., Kirchhausen T. 2010; The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis. PLoS Pathog 6:e1001127 [View Article][PubMed]
    [Google Scholar]
  28. Dal Canto M. C., Rabinowitz S. G., Johnson T. C. 1976; Status spongiosus resulting from intracerebral infection of mice with temperature-sensitive mutants of vesicular stomatitis virus. Br J Exp Pathol 57:321–330[PubMed]
    [Google Scholar]
  29. Dalton K. P., Rose J. K. 2001; Vesicular stomatitis virus glycoprotein containing the entire green fluorescent protein on its cytoplasmic domain is incorporated efficiently into virus particles. Virology 279:414–421 [View Article][PubMed]
    [Google Scholar]
  30. Diallo J. S., Vähä-Koskela M., Le Boeuf F., Bell J. 2012; Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. Methods Mol Biol 797:127–140 [View Article][PubMed]
    [Google Scholar]
  31. Diaz R. M., Galivo F., Kottke T., Wongthida P., Qiao J., Thompson J., Valdes M., Barber G., Vile R. G. 2007; Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67:2840–2848 [View Article][PubMed]
    [Google Scholar]
  32. Dinh P. X., Beura L. K., Panda D., Das A., Pattnaik A. K. 2011; Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression. J Virol 85:9459–9471 [View Article][PubMed]
    [Google Scholar]
  33. Drolet B. S., Stuart M. A., Derner J. D. 2009; Infection of Melanoplus sanguinipes grasshoppers following ingestion of rangeland plant species harboring vesicular stomatitis virus. Appl Environ Microbiol 75:3029–3033 [View Article][PubMed]
    [Google Scholar]
  34. Ebert O., Shinozaki K., Kournioti C., Park M. S., García-Sastre A., Woo S. L. 2004; Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 64:3265–3270 [View Article][PubMed]
    [Google Scholar]
  35. Edge R. E., Falls T. J., Brown C. W., Lichty B. D., Atkins H., Bell J. C. 2008; A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 16:1437–1443 [View Article][PubMed]
    [Google Scholar]
  36. Egan M. A., Chong S. Y., Rose N. F., Megati S., Lopez K. J., Schadeck E. B., Johnson J. E., Masood A., Piacente P. other authors 2004; Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20:989–1004 [View Article][PubMed]
    [Google Scholar]
  37. Faria P. A., Chakraborty P., Levay A., Barber G. N., Ezelle H. J., Enninga J., Arana C., van Deursen J., Fontoura B. M. 2005; VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 17:93–102 [View Article][PubMed]
    [Google Scholar]
  38. Fernandez M., Porosnicu M., Markovic D., Barber G. N. 2002; Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76:895–904 [View Article][PubMed]
    [Google Scholar]
  39. Finke S., Conzelmann K. K. 2005; Recombinant rhabdoviruses: vectors for vaccine development and gene therapy. Curr Top Microbiol Immunol 292:165–200 [View Article][PubMed]
    [Google Scholar]
  40. Flanagan E. B., Zamparo J. M., Ball L. A., Rodriguez L. L., Wertz G. W. 2001; Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75:6107–6114 [View Article][PubMed]
    [Google Scholar]
  41. Frei K., Malipiero U. V., Leist T. P., Zinkernagel R. M., Schwab M. E., Fontana A. 1989; On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689–694 [View Article][PubMed]
    [Google Scholar]
  42. Friedman G. K., Cassady K. A., Beierle E. A., Markert J. M., Gillespie G. Y. 2012; Targeting pediatric cancer stem cells with oncolytic virotherapy. Pediatr Res 71:500–510 [View Article][PubMed]
    [Google Scholar]
  43. Furr S. R., Chauhan V. S., Sterka D. Jr, Grdzelishvili V. Z., Marriott I. 2008; Characterization of retinoic acid-inducible gene-I expression in primary murine glia following exposure to vesicular stomatitis virus. J Neurovirol 14:503–513[PubMed] [CrossRef]
    [Google Scholar]
  44. Furr S. R., Moerdyk-Schauwecker M., Grdzelishvili V. Z., Marriott I. 2010; RIG-I mediates nonsegmented negative-sense RNA virus-induced inflammatory immune responses of primary human astrocytes. Glia 58:1620–1629[PubMed]
    [Google Scholar]
  45. Gaddy D. F., Lyles D. S. 2005; Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79:4170–4179 [View Article][PubMed]
    [Google Scholar]
  46. Gaddy D. F., Lyles D. S. 2007; Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 81:2792–2804 [View Article][PubMed]
    [Google Scholar]
  47. Galivo F., Diaz R. M., Thanarajasingam U., Jevremovic D., Wongthida P., Thompson J., Kottke T., Barber G. N., Melcher A., Vile R. G. 2010; Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21:439–450 [View Article][PubMed]
    [Google Scholar]
  48. Gao Y., Whitaker-Dowling P., Watkins S. C., Griffin J. A., Bergman I. 2006; Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol 80:8603–8612 [View Article][PubMed]
    [Google Scholar]
  49. Garber K. 2006; China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98:298–300 [View Article][PubMed]
    [Google Scholar]
  50. Ge P., Tsao J., Schein S., Green T. J., Luo M., Zhou Z. H. 2010; Cryo-EM model of the bullet-shaped vesicular stomatitis virus. Science 327:689–693 [View Article][PubMed]
    [Google Scholar]
  51. Georgel P., Jiang Z., Kunz S., Janssen E., Mols J., Hoebe K., Bahram S., Oldstone M. B., Beutler B. 2007; Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. Virology 362:304–313 [View Article][PubMed]
    [Google Scholar]
  52. Ghiringhelli F., Menard C., Puig P. E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B. 2007; Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648 [View Article][PubMed]
    [Google Scholar]
  53. Goel A., Carlson S. K., Classic K. L., Greiner S., Naik S., Power A. T., Bell J. C., Russell S. J. 2007; Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 110:2342–2350 [View Article][PubMed]
    [Google Scholar]
  54. Hamacher R., Schmid R. M., Saur D., Schneider G. 2008; Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 7:64 [View Article][PubMed]
    [Google Scholar]
  55. Hammill A. M., Conner J., Cripe T. P. 2010; Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 55:1253–1263 [View Article][PubMed]
    [Google Scholar]
  56. Hanahan D., Weinberg R. A. 2011; Hallmarks of cancer: the next generation. Cell 144:646–674 [View Article][PubMed]
    [Google Scholar]
  57. Hansen D. E., Thurmond M. C., Thorburn M. 1985; Factors associated with the spread of clinical vesicular stomatitis in California dairy cattle. Am J Vet Res 46:789–795[PubMed]
    [Google Scholar]
  58. Harashima A., Guettouche T., Barber G. N. 2010; Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. Genes Dev 24:2640–2653 [View Article][PubMed]
    [Google Scholar]
  59. Heiber J. F., Barber G. N. 2011; Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol 85:10440–10450 [View Article][PubMed]
    [Google Scholar]
  60. Heinrich B. S., Cureton D. K., Rahmeh A. A., Whelan S. P. 2010; Protein expression redirects vesicular stomatitis virus RNA synthesis to cytoplasmic inclusions. PLoS Pathog 6:e1000958 [View Article][PubMed]
    [Google Scholar]
  61. Hoffmann M., Wu Y. J., Gerber M., Berger-Rentsch M., Heimrich B., Schwemmle M., Zimmer G. 2010; Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. J Gen Virol 91:2782–2793 [View Article][PubMed]
    [Google Scholar]
  62. Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K. K. other authors 2006; 5′-Triphosphate RNA is the ligand for RIG-I. Science 314:994–997 [View Article][PubMed]
    [Google Scholar]
  63. Huneycutt B. S., Bi Z., Aoki C. J., Reiss C. S. 1993; Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 67:6698–6706[PubMed]
    [Google Scholar]
  64. Ikeda K., Wakimoto H., Ichikawa T., Jhung S., Hochberg F. H., Louis D. N., Chiocca E. A. 2000; Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74:4765–4775 [View Article][PubMed]
    [Google Scholar]
  65. Irie T., Carnero E., Okumura A., García-Sastre A., Harty R. N. 2007; Modifications of the PSAP region of the matrix protein lead to attenuation of vesicular stomatitis virus in vitro and in vivo . J Gen Virol 88:2559–2567 [View Article][PubMed]
    [Google Scholar]
  66. Janelle V., Brassard F., Lapierre P., Lamarre A., Poliquin L. 2011; Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol 85:6513–6520 [View Article][PubMed]
    [Google Scholar]
  67. Jenks N., Myers R., Greiner S. M., Thompson J., Mader E. K., Greenslade A., Griesmann G. E., Federspiel M. J., Rakela J. other authors 2010; Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-β in rodents and nonhuman primates. Hum Gene Ther 21:451–462 [View Article][PubMed]
    [Google Scholar]
  68. Jensen H., Andresen L., Nielsen J., Christensen J. P., Skov S. 2011; Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. PLoS ONE 6:e23023 [View Article][PubMed]
    [Google Scholar]
  69. Johnson J. E., Nasar F., Coleman J. W., Price R. E., Javadian A., Draper K., Lee M., Reilly P. A., Clarke D. K. other authors 2007; Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360:36–49 [View Article][PubMed]
    [Google Scholar]
  70. Kelly E., Russell S. J. 2007; History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651–659[PubMed] [CrossRef]
    [Google Scholar]
  71. Kelly E. J., Nace R., Barber G. N., Russell S. J. 2010; Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 84:1550–1562 [View Article][PubMed]
    [Google Scholar]
  72. Kopecky S. A., Willingham M. C., Lyles D. S. 2001; Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol 75:12169–12181 [View Article][PubMed]
    [Google Scholar]
  73. Kottke T., Diaz R. M., Kaluza K., Pulido J., Galivo F., Wongthida P., Thompson J., Willmon C., Barber G. N. other authors 2008a; Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 16:1910–1918 [View Article][PubMed]
    [Google Scholar]
  74. Kottke T., Galivo F., Wongthida P., Diaz R. M., Thompson J., Jevremovic D., Barber G. N., Hall G., Chester J. other authors 2008b; Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 16:1217–1226 [View Article][PubMed]
    [Google Scholar]
  75. Kottke T., Hall G., Pulido J., Diaz R. M., Thompson J., Chong H., Selby P., Coffey M., Pandha H. other authors 2010; Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 120:1551–1560 [View Article][PubMed]
    [Google Scholar]
  76. Krishnamoorthy J., Mounir Z., Raven J. F., Koromilas A. E. 2008; The eIF2α kinases inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation. Cell Cycle 7:2346–2351[PubMed] [CrossRef]
    [Google Scholar]
  77. Labib M., Zamay A. S., Muharemagic D., Chechik A., Bell J. C., Berezovski M. V. 2012; Electrochemical sensing of aptamer-facilitated virus immunoshielding. Anal Chem 84:1677–1686 [View Article][PubMed]
    [Google Scholar]
  78. Lawson N. D., Stillman E. A., Whitt M. A., Rose J. K. 1995; Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92:4477–4481 [View Article][PubMed]
    [Google Scholar]
  79. Le Boeuf F., Diallo J. S., McCart J. A., Thorne S., Falls T., Stanford M., Kanji F., Auer R., Brown C. W. other authors 2010; Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18:888–895 [View Article][PubMed]
    [Google Scholar]
  80. Le Boeuf F., Niknejad N., Wang J., Auer R., Weberpals J. I., Bell J. C., Dimitroulakos J. 2012; Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Int J Cancer 131:E204–E215 [View Article][PubMed]
    [Google Scholar]
  81. Leveille S., Goulet M. L., Lichty B. D., Hiscott J. 2011a; Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol 85:12160–12169 [View Article][PubMed]
    [Google Scholar]
  82. Leveille S., Samuel S., Goulet M. L., Hiscott J. 2011b; Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 18:435–443 [View Article][PubMed]
    [Google Scholar]
  83. Li Q., Tainsky M. A. 2011; Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS ONE 6:e28683 [View Article][PubMed]
    [Google Scholar]
  84. Lichty B. D., Power A. T., Stojdl D. F., Bell J. C. 2004; Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10:210–216 [View Article][PubMed]
    [Google Scholar]
  85. Linge C., Gewert D., Rossmann C., Bishop J. A., Crowe J. S. 1995; Interferon system defects in human malignant melanoma. Cancer Res 55:4099–4104[PubMed]
    [Google Scholar]
  86. Lyles D. S., Rupprecht C. E. 2007; Rhabdoviridae . In Fields Virology, 5th edn. pp. 1363–1408 Edited by Knipe D. M., Howley P. M. Philadelphia, PA: Lippincott Williams & Wilkins;
    [Google Scholar]
  87. Marozin S., Altomonte J., Stadler F., Thasler W. E., Schmid R. M., Ebert O. 2008; Inhibition of the IFN-β response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol Ther 16:1789–1797 [View Article][PubMed]
    [Google Scholar]
  88. Marozin S., De Toni E. N., Rizzani A., Altomonte J., Junger A., Schneider G., Thasler W. E., Kato N., Schmid R. M., Ebert O. 2010; Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. PLoS ONE 5:e10988 [View Article][PubMed]
    [Google Scholar]
  89. Martinez I., Rodriguez L. L., Jimenez C., Pauszek S. J., Wertz G. W. 2003; Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 77:8039–8047 [View Article][PubMed]
    [Google Scholar]
  90. Matin S. F., Rackley R. R., Sadhukhan P. C., Kim M. S., Novick A. C., Bandyopadhyay S. K. 2001; Impaired α-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res 61:2261–2266[PubMed]
    [Google Scholar]
  91. Melcher A., Parato K., Rooney C. M., Bell J. C. 2011; Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19:1008–1016 [View Article][PubMed]
    [Google Scholar]
  92. Miller J., Bidula S. M., Jensen T. M., Reiss C. S. 2009; Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic. Int J Infereron Cytokine Mediator Res 1:15–32[PubMed]
    [Google Scholar]
  93. Miller J. M., Bidula S. M., Jensen T. M., Reiss C. S. 2010; Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo . Int J Infereron Cytokine Mediator Res 2010:63–72[PubMed]
    [Google Scholar]
  94. Mire C. E., Whitt M. A. 2011; The protease-sensitive loop of the vesicular stomatitis virus matrix protein is involved in virus assembly and protein translation. Virology 416:16–25 [View Article][PubMed]
    [Google Scholar]
  95. Moerdyk-Schauwecker M., Destephanis D., Hastie E., Grdzelishvili V. Z. 2011; Detecting protein–protein interactions in vesicular stomatitis virus using a cytoplasmic yeast two hybrid system. J Virol Methods 173:203–212 [View Article][PubMed]
    [Google Scholar]
  96. Moussavi M., Fazli L., Tearle H., Guo Y., Cox M., Bell J., Ong C., Jia W., Rennie P. S. 2010; Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res 70:1367–1376 [View Article][PubMed]
    [Google Scholar]
  97. Muik A., Kneiske I., Werbizki M., Wilflingseder D., Giroglou T., Ebert O., Kraft A., Dietrich U., Zimmer G. other authors 2011; Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 85:5679–5684 [View Article][PubMed]
    [Google Scholar]
  98. Muik A., Dold C., Geiß Y., Volk A., Werbizki M., Dietrich U., von Laer D. 2012; Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) 90:959–970 [View Article][PubMed]
    [Google Scholar]
  99. Murphy A. M., Besmer D. M., Moerdyk-Schauwecker M., Moestl N., Ornelles D. A., Mukherjee P., Grdzelishvili V. Z. 2012; Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol 86:3073–3087 [View Article][PubMed]
    [Google Scholar]
  100. Naik S., Russell S. J. 2009; Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther 9:1163–1176 [View Article][PubMed]
    [Google Scholar]
  101. Naik S., Nace R., Federspiel M. J., Barber G. N., Peng K. W., Russell S. J. 2012; Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26:1870–1878 [View Article][PubMed]
    [Google Scholar]
  102. Nakashima H., Kaur B., Chiocca E. A. 2010; Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 21:119–126 [View Article][PubMed]
    [Google Scholar]
  103. Nguyên T. L., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J. S., Yasmeen A., Bismar T. A., Kirn D. other authors 2008; Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 105:14981–14986 [View Article][PubMed]
    [Google Scholar]
  104. Noser J. A., Mael A. A., Sakuma R., Ohmine S., Marcato P., Lee P. W., Ikeda Y. 2007; The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 15:1531–1536 [View Article][PubMed]
    [Google Scholar]
  105. Obuchi M., Fernandez M., Barber G. N. 2003; Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 77:8843–8856 [View Article][PubMed]
    [Google Scholar]
  106. Oliere S., Arguello M., Mesplede T., Tumilasci V., Nakhaei P., Stojdl D., Sonenberg N., Bell J., Hiscott J. 2008; Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 82:5735–5749 [View Article][PubMed]
    [Google Scholar]
  107. Ozduman K., Wollmann G., Ahmadi S. A., van den Pol A. N. 2009; Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain. J Virol 83:11540–11549 [View Article][PubMed]
    [Google Scholar]
  108. Pearson A. S., Koch P. E., Atkinson N., Xiong M., Finberg R. W., Roth J. A., Fang B. 1999; Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 5:4208–4213[PubMed]
    [Google Scholar]
  109. Peng K. W., Myers R., Greenslade A., Mader E., Greiner S., Federspiel M. J., Dispenzieri A., Russell S. J. 2012; Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (in press). doi:10.1038/gt.2012.31 [View Article][PubMed]
    [Google Scholar]
  110. Petersen J. M., Her L. S., Varvel V., Lund E., Dahlberg J. E. 2000; The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 20:8590–8601 [View Article][PubMed]
    [Google Scholar]
  111. Pfeffer L. M., Wang C., Constantinescu S. N., Croze E., Blatt L. M., Albino A. P., Nanus D. M. 1996; Human renal cancers resistant to IFN’s antiproliferative action exhibit sensitivity to IFN’s gene-inducing and antiviral actions. J Urol 156:1867–1871 [View Article][PubMed]
    [Google Scholar]
  112. Plakhov I. V., Arlund E. E., Aoki C., Reiss C. S. 1995; The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 209:257–262 [View Article][PubMed]
    [Google Scholar]
  113. Porosnicu M., Mian A., Barber G. N. 2003; The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 63:8366–8376[PubMed]
    [Google Scholar]
  114. Power A. T., Bell J. C. 2007; Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15:660–665[PubMed] [CrossRef]
    [Google Scholar]
  115. Power A. T., Bell J. C. 2008; Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 15:772–779 [View Article][PubMed]
    [Google Scholar]
  116. Pulido J., Kottke T., Thompson J., Galivo F., Wongthida P., Diaz R. M., Rommelfanger D., Ilett E., Pease L. other authors 2012; Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30:337–343 [View Article][PubMed]
    [Google Scholar]
  117. Qiao J., Wang H., Kottke T., Diaz R. M., Willmon C., Hudacek A., Thompson J., Parato K., Bell J. other authors 2008a; Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 15:604–616 [View Article][PubMed]
    [Google Scholar]
  118. Qiao J., Wang H., Kottke T., White C., Twigger K., Diaz R. M., Thompson J., Selby P., de Bono J. other authors 2008b; Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14:259–269 [View Article][PubMed]
    [Google Scholar]
  119. Quiroz E., Moreno N., Peralta P. H., Tesh R. B. 1988; A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 39:312–314[PubMed]
    [Google Scholar]
  120. Reiss C. S., Plakhov I. V., Komatsu T. 1998; Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci 855:751–761 [View Article][PubMed]
    [Google Scholar]
  121. Rieder M., Conzelmann K. K. 2009; Rhabdovirus evasion of the interferon system. J Interferon Cytokine Res 29:499–510 [View Article][PubMed]
    [Google Scholar]
  122. Rose N. F., Marx P. A., Luckay A., Nixon D. F., Moretto W. J., Donahoe S. M., Montefiori D., Roberts A., Buonocore L., Rose J. K. 2001; An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539–549 [View Article][PubMed]
    [Google Scholar]
  123. Saloura V., Wang L. C., Fridlender Z. G., Sun J., Cheng G., Kapoor V., Sterman D. H., Harty R. N., Okumura A. other authors 2010; Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther 21:51–64 [View Article][PubMed]
    [Google Scholar]
  124. Samuel S., Tumilasci V. F., Oliere S., Nguyên T. L., Shamy A., Bell J., Hiscott J. 2010; VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther 18:2094–2103 [View Article][PubMed]
    [Google Scholar]
  125. Sarojini S., Theofanis T., Reiss C. S. 2011; Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons. DNA Cell Biol 30:965–974 [View Article][PubMed]
    [Google Scholar]
  126. Schache P., Gürlevik E., Strüver N., Woller N., Malek N., Zender L., Manns M., Wirth T., Kühnel F., Kubicka S. 2009; VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther 16:849–861 [View Article][PubMed]
    [Google Scholar]
  127. Schellekens H., Smiers-de Vreede E., de Reus A., Dijkema R. 1984; Antiviral activity of interferon in rats and the effect of immune suppression. J Gen Virol 65:391–396 [View Article][PubMed]
    [Google Scholar]
  128. Schnell M. J., Buonocore L., Kretzschmar E., Johnson E., Rose J. K. 1996; Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A 93:11359–11365 [View Article][PubMed]
    [Google Scholar]
  129. Sharif-Askari E., Nakhaei P., Oliere S., Tumilasci V., Hernandez E., Wilkinson P., Lin R., Bell J., Hiscott J. 2007; Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology 365:20–33 [View Article][PubMed]
    [Google Scholar]
  130. Shi Z., Cai Z., Sanchez A., Zhang T., Wen S., Wang J., Yang J., Fu S., Zhang D. 2011; A novel Toll-like receptor that recognizes vesicular stomatitis virus. J Biol Chem 286:4517–4524 [View Article][PubMed]
    [Google Scholar]
  131. Shin E. J., Wanna G. B., Choi B., Aguila D. III, Ebert O., Genden E. M., Woo S. L. 2007a; Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 117:210–214 [View Article][PubMed]
    [Google Scholar]
  132. Shin E. J., Chang J. I., Choi B., Wanna G., Ebert O., Genden E. M., Woo S. L. 2007b; Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg 136:811–817 [View Article][PubMed]
    [Google Scholar]
  133. Shinozaki K., Ebert O., Suriawinata A., Thung S. N., Woo S. L. 2005; Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J Virol 79:13705–13713 [View Article][PubMed]
    [Google Scholar]
  134. Staeheli P., Pavlovic J. 1991; Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein. J Virol 65:4498–4501[PubMed]
    [Google Scholar]
  135. Stanifer M. L., Cureton D. K., Whelan S. P. 2011; A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion. J Virol 85:8105–8115 [View Article][PubMed]
    [Google Scholar]
  136. Stephenson K. B., Barra N. G., Davies E., Ashkar A. A., Lichty B. D. 2012; Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 19:238–246 [View Article][PubMed]
    [Google Scholar]
  137. Stojdl D. F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J. C. 2000; Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821–825 [View Article][PubMed]
    [Google Scholar]
  138. Stojdl D. F., Lichty B. D., tenOever B. R., Paterson J. M., Power A. T., Knowles S., Marius R., Reynard J., Poliquin L. other authors 2003; VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263–275 [View Article][PubMed]
    [Google Scholar]
  139. Sun W. H., Pabon C., Alsayed Y., Huang P. P., Jandeska S., Uddin S., Platanias L. C., Rosen S. T. 1998; Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91:570–576[PubMed]
    [Google Scholar]
  140. Tumilasci V. F., Olière S., Nguyên T. L., Shamy A., Bell J., Hiscott J. 2008; Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 82:8487–8499 [View Article][PubMed]
    [Google Scholar]
  141. van den Pol A. N., Dalton K. P., Rose J. K. 2002; Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 76:1309–1327 [View Article][PubMed]
    [Google Scholar]
  142. Wang B. X., Rahbar R., Fish E. N. 2011; Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 31:545–552 [View Article][PubMed]
    [Google Scholar]
  143. Weidner J. M., Jiang D., Pan X. B., Chang J., Block T. M., Guo J. T. 2010; Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84:12646–12657 [View Article][PubMed]
    [Google Scholar]
  144. Whelan S. P., Ball L. A., Barr J. N., Wertz G. T. 1995; Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 92:8388–8392 [View Article][PubMed]
    [Google Scholar]
  145. Whitlow Z. W., Connor J. H., Lyles D. S. 2006; Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol 80:11733–11742 [View Article][PubMed]
    [Google Scholar]
  146. Whitlow Z. W., Connor J. H., Lyles D. S. 2008; New mRNAs are preferentially translated during vesicular stomatitis virus infection. J Virol 82:2286–2294 [View Article][PubMed]
    [Google Scholar]
  147. Willmon C., Diaz R. M., Wongthida P., Galivo F., Kottke T., Thompson J., Albelda S., Harrington K., Melcher A., Vile R. 2011; Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther 19:140–149 [View Article][PubMed]
    [Google Scholar]
  148. Wollmann G., Tattersall P., van den Pol A. N. 2005; Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol 79:6005–6022 [View Article][PubMed]
    [Google Scholar]
  149. Wollmann G., Rogulin V., Simon I., Rose J. K., van den Pol A. N. 2010; Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol 84:1563–1573 [View Article][PubMed]
    [Google Scholar]
  150. Wong L. H., Krauer K. G., Hatzinisiriou I., Estcourt M. J., Hersey P., Tam N. D., Edmondson S., Devenish R. J., Ralph S. J. 1997; Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem 272:28779–28785 [View Article][PubMed]
    [Google Scholar]
  151. Wongthida P., Diaz R. M., Galivo F., Kottke T., Thompson J., Pulido J., Pavelko K., Pease L., Melcher A., Vile R. 2010; Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 70:4539–4549 [View Article][PubMed]
    [Google Scholar]
  152. Wongthida P., Diaz R. M., Galivo F., Kottke T., Thompson J., Melcher A., Vile R. 2011a; VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther 19:150–158 [View Article][PubMed]
    [Google Scholar]
  153. Wongthida P., Diaz R. M., Pulido C., Rommelfanger D., Galivo F., Kaluza K., Kottke T., Thompson J., Melcher A., Vile R. 2011b; Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther 22:1343–1353 [View Article][PubMed]
    [Google Scholar]
  154. Wu L., Huang T. G., Meseck M., Altomonte J., Ebert O., Shinozaki K., García-Sastre A., Fallon J., Mandeli J., Woo S. L. 2008; rVSV(MΔ51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum Gene Ther 19:635–647 [View Article][PubMed]
    [Google Scholar]
  155. Yuan H., Puckett S., Lyles D. S. 2001; Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-binding protein (TBP) or association of TBP with TBP-associated factor subunits. J Virol 75:4453–4458 [View Article][PubMed]
    [Google Scholar]
  156. Zhang K. X., Matsui Y., Hadaschik B. A., Lee C., Jia W., Bell J. C., Fazli L., So A. I., Rennie P. S. 2010; Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int J Cancer 127:830–838[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.046672-0
Loading
/content/journal/jgv/10.1099/vir.0.046672-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error